Digitisation | May 23, 2024
Indica Labs receives FDA clearance for HALO AP Dx digital pathology platform
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
The proposed facility is expected to be operational around January, 2027
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
A significant proportion of healthcare professionals still tend to favor branded drugs
Subscribe To Our Newsletter & Stay Updated
